Lithium Versus Quetiapine in Treatment Resistant Depression
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
LQD is a multicentre randomised clinical trial comparing the clinical and cost effectiveness
of lithium versus quetiapine when used as add-on therapies to antidepressant medication for
patients with treatment resistant depression. The Lithium versus Quetiapine in Depression
(LQD) study will assess patients over 12 months to establish which (if any) treatment is more
likely to improve TRD over a long duration of time. Professor Anthony Cleare is the Chief
Investigator and recruitment began in November 2016.
Phase:
Phase 4
Details
Lead Sponsor:
King's College London
Collaborators:
Avon and Wiltshire Mental Health Partnership NHS Trust Newcastle University Northumberland, Tyne and Wear NHS Foundation Trust Oxford Health NHS Foundation Trust South London and Maudsley NHS Foundation Trust Sussex Partnership NHS Foundation Trust Tees, Esk and Wear Valleys NHS Foundation Trust University of Oxford